We caught up with Dr. Vincent Joustra (AGEM University of Amsterdam, Amsterdam, The Netherlands) around his cohort study investigating predictive biomarkers for response to vedolizumab in Crohn’s disease.
The abstract entitled ‘Peripheral blood DNA methylation biomarkers accurately predict clinical- and endoscopic response to vedolizumab in a real-life cohort of Crohn’s Disease patients’ (Presentation no. OP29) was presented at the 17th Congress of ECCO, February 16-19, 2022!
Questions
- Why is there a need for predictive biomarkers for response to vedolizumab in Crohn’s disease? (0:59)
- What were the aims, design and inclusion criteria of the cohort study you are presenting? (2:38)
- What were the findings in terms of biomarker identification? (4:14)
- How easy will it be to incorporate analysis of these biomarkers into routine clinical practice? (5:18)
- What questions remain unanswered and what future studies are planned? (6:57)
Disclosures: Vincent Joustra has nothing to disclose in relation to this interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ECCO-IBD virtual 2022.
